Lupin to file application for biosimilar etanercept in EU, Japan in next quarter1 min read . Updated: 08 Feb 2018, 01:22 AM IST
YL Biologics, a JV of Lupin and Japanese firm Yoshindo, says phase-III trial of Etanercept met the primary endpoint and the product's safety and immunogenicity was found to be similar to the reference drug Enbrel
Mumbai: Lupin Ltd plans to file an application for its biosimilar Etanercept with regulators in Europe and Japan during the next quarter following positive results displayed by the product in phase-III clinical trials.
Select your Category